Plaquenil (hydroxychloroquine) is technically classified as an immunomodulator, not a traditional immunosuppressant, though the line between the two is blurrier than most people realize. In lab settings, it clearly suppresses certain immune functions. But at the doses people actually take for lupus or rheumatoid arthritis, its effects are far more targeted and gentle than drugs like cyclophosphamide or prednisone. This distinction matters because it shapes your infection risk, your ability to respond to vaccines, and whether you can safely take it during pregnancy.
How Plaquenil Affects the Immune System
Plaquenil works by accumulating inside lysosomes, the small acidic compartments your cells use to break down waste and process immune signals. Once inside, it raises the pH of these compartments, making them less acidic. This disrupts a chain of immune communication that would otherwise trigger inflammation.
More specifically, Plaquenil interferes with a family of sensors called toll-like receptors (TLRs 3, 7, 8, and 9) that sit inside your cells and detect fragments of genetic material. In autoimmune diseases like lupus, these sensors become overactive and start reacting to the body’s own DNA and RNA as if they were foreign invaders. Plaquenil dials down that false alarm by preventing these sensors from binding to their triggers and releasing inflammatory signals. It also affects how immune cells present pieces of proteins to other immune cells, which helps calm the broader immune response.
Immunomodulator vs. Immunosuppressant
A true immunosuppressant broadly dampens your immune system’s ability to function. Drugs like cyclophosphamide or high-dose steroids suppress the growth and activity of B cells and T cells, the core players in both your adaptive immunity and your autoimmune disease. Plaquenil doesn’t work this way at normal doses.
A 2023 clinical pharmacology study illustrates the gap between lab results and real-world effects. In cell cultures, hydroxychloroquine powerfully suppressed immune responses, reaching 100% inhibition of toll-like receptor signaling at concentrations above 100 nanograms per milliliter. But in actual patients taking standard doses for five days, blood concentrations peaked between 75 and 200 ng/mL, and the drug only significantly suppressed one specific pathway (TLR7 responses). It did not affect B cell or T cell proliferation at all. The researchers concluded that while Plaquenil has clear immunosuppressive properties in a test tube, circulating drug levels during normal use fall short of what’s needed for broad suppression. Local tissue concentrations may be higher, potentially creating targeted effects at sites of inflammation without systemic immune shutdown.
This is why rheumatologists often describe Plaquenil as an immunomodulator: it fine-tunes specific overactive immune pathways rather than turning down the whole system.
What Plaquenil Is Approved to Treat
The FDA approves Plaquenil for rheumatoid arthritis, systemic lupus erythematosus, and chronic discoid lupus erythematosus in adults. It’s also approved for treating and preventing malaria in both adults and children. In practice, doctors prescribe it for other autoimmune conditions like Sjögren’s syndrome as well, though that use is off-label.
Symptom improvement typically begins within one to two months, but the full benefit can take up to six months, according to the American College of Rheumatology. This slow onset reflects its mechanism: rather than bluntly suppressing inflammation, it gradually recalibrates the immune signals driving the disease.
Infection Risk Is Lower Than With Other Drugs
One of Plaquenil’s biggest practical advantages is that it doesn’t leave you as vulnerable to infections as conventional immunosuppressants do. A systematic review and meta-analysis of lupus patients found that hydroxychloroquine use was associated with a 23% lower chance of infection overall, though this trend didn’t reach statistical significance. The more striking finding was in serious infections: patients taking hydroxychloroquine had a 60% lower risk of severe infections compared to those not taking it (a statistically significant result). By contrast, lupus patients who develop infections tend to be the ones using glucocorticoids and stronger immunosuppressants more heavily.
This profile is a major reason Plaquenil is considered a cornerstone of lupus treatment. It helps control the disease without creating the infection vulnerability that comes with more aggressive drugs.
Vaccines and Plaquenil
There is evidence that hydroxychloroquine and its close relative chloroquine can blunt your immune response to certain vaccines. Studies have shown reduced antibody responses to rabies, tetanus, and diphtheria vaccines in people taking chloroquine. The mechanism makes sense: by raising the pH inside lysosomes, the drug interferes with how immune cells process and present vaccine antigens, and with how B cells get activated to produce antibodies.
This doesn’t mean vaccines won’t work at all if you’re on Plaquenil, but your response may be somewhat weaker. It’s worth discussing timing with whoever manages your care if you’re due for vaccinations, particularly for travel-related immunizations or during outbreak seasons.
Safe During Pregnancy and Breastfeeding
Unlike most drugs that affect the immune system, Plaquenil has a reassuring safety profile during pregnancy. The Society for Maternal Fetal Medicine recommends that pregnant people with lupus continue or even start hydroxychloroquine. Several studies have found no increased risk of miscarriage, birth defects, preterm delivery, or low birth weight. There’s even evidence it may reduce the chance of congenital heart block in pregnancies already at elevated risk for that condition.
Although retinal toxicity is a known long-term side effect of Plaquenil in adults (more on that below), studies of young children born to mothers who took it during pregnancy have not found increased eye problems. The drug does pass into breast milk in small amounts, but studies tracking infants up to about one year of age have reported no harmful effects on vision, hearing, or growth.
Long-Term Monitoring for Eye Health
The one side effect that requires ongoing attention is retinal toxicity. Hydroxychloroquine can damage the retina over time, particularly at higher doses or with prolonged use. To minimize this risk, the American Academy of Ophthalmology recommends keeping the dose at or below 5 mg per kilogram of actual body weight per day.
You should have a full baseline eye exam, including optical coherence tomography (OCT) and fundus autofluorescence imaging, soon after starting the drug. Annual screening is recommended, though if you have no significant risk factors, screening can be deferred during the first five years of use. If your eye doctor spots subtle or unclear changes on these primary tests, additional testing with visual field exams or specialized electrical recordings of retinal function can help confirm whether toxicity is developing. Catching changes early allows you to stop the drug before vision loss becomes permanent.
Where Plaquenil Fits Among Immune-Targeting Drugs
Think of immune-targeting medications on a spectrum. At one end are powerful immunosuppressants like cyclophosphamide, which broadly shut down immune cell production and carry significant infection risk. In the middle are drugs like methotrexate and mycophenolate, which suppress specific immune pathways more selectively. Plaquenil sits at the gentler end of this spectrum. It modulates immune signaling, particularly the toll-like receptor pathways that drive autoimmune flares, without broadly suppressing immune cell counts or function.
This is why Plaquenil is often the first drug started in lupus and why it’s frequently continued even when stronger medications are added. It provides a baseline of immune modulation with a safety profile that allows long-term use, pregnancy compatibility, and a lower infection burden than nearly any other drug in the autoimmune toolkit.